InfanDx AG focuses on the development and commercialization of novel diagnostic solutions specifically designed to support clinicians in the management of acute and critical care conditions in newborns.
The proprietary lead product in clinical development is the InfanDx HypoxE® Test for the rapid and reliable diagnosis of perinatal Asphyxia (oxygen deficit during birth) and early identification and prognosis of Hypoxic-Ischemic Encephalopathy (HIE), brain injuries that can result in life-long disabilities.
InfanDx is located at the BioCampus Cologne in the West of Germany.
Precision Medicine denotes an emerging treatment approach that takes into account individual genetic & genomic features as well as environmental influences and lifestyles. The Institute of Precision Medicine employs 3rd generation sequencing, metabolomics and other high-throughput technologies as well as data mining utilizing recorded clinical data to research strategies for diagnosing and treating diseases much more precisely.
At HFU, InfanDx works with Prof. Dr. Hans-Peter Deigner, one of the most distinguished experts in metabolomics, and his team in the discovery and validation of biomarkers for HIE. For clinical study design and biostatistical analysis and AI driven approaches to HIE diagnosis, InfanDx works with Prof. Dr. Matthias Kohl, a leading biostatistician, and his team.
CPCS, led by Prof. Dr. Axel Franz, is an academic CRO at the University Hospital Tübingen specialized in clinical studies in children. CPCS provides the entire spectrum of services including study planning, protocol approval, study execution, monitoring, data management, biometric analyses, and reporting in compliance with all applicable laws, regulations, and quality standards.
Headed by Prof. Dr. Ursula Felderhoff-Müser, the clinic specializes in the diagnosis and treatment of neuro-pediatric/neonataldiseases, pediatric emergency and intensive medicine. InfanDx collaborates with Prof. Felderhoff and her team in clinical studies and biomarker research in HIE.